Bratha

Part 3.1 - The Pharmacological Reset

23 min read

This is Part 3 of 5 in the Sleep Series — the prescription tier, and the last resort. The full path:

Table of Contents

This is the prescription tier — read this first

Every compound in this article is a prescription (and in some cases controlled) medicine. Nothing here is a recommendation to obtain or use any of them without a doctor. This is harm-reduction information for someone who has exhausted the environment, the protocol, and the OTC layer, and is going to have an informed conversation with a physician about the better-designed options — so they can avoid the genuinely dangerous ones. If you haven’t done the first 90%, the answer to your sleep problem is not in this article.

The frame: a bridge, not a crutch

There are exactly two legitimate reasons to be on this page:

  1. You’ve genuinely optimised everything else — room, routine, OTC layer, given it weeks — and you’re still not sleeping. This is real; some insomnia outlasts perfect hygiene.
  2. You’re starting from a wrecked pattern so broken that habits can’t take hold — chronic 4 AM sleep onset, shift-work damage, a months-long insomnia spiral — and you need to force a reset before the behavioural foundation can even begin to work.

In both cases the goal is the same, and it’s the thesis of this entire article:

==Pharmacology here is a bridge to rebuild your sleep architecture and your habits over ~30 days — then you walk off it.== It is not a nightly crutch you take forever. You use a well-chosen drug to force consistent, well-architected sleep for a month — long enough to drag your circadian clock into place (Part 1.0), long enough to condition the “bed = sleep” association and the wind-down ritual from Parts 2.0/2.1 — and then you taper off and hand control back to the habits, which by then are doing the work.

This is the same logic as the 10 rule, one more time: the drug is a temporary amplifier of a foundation you’ve already built. A pharmacological reset on top of a broken foundation just relapses the moment you stop. That’s why Parts 2.0–3.0 aren’t optional prerequisites — they’re the thing the drug is bridging you toward.

The principle that sorts good drugs from bad: sedation is not sleep

The single idea that separates a smart sleep drug from a dumb one — and it’s the same point made about alcohol in Part 2.1:

==Knocking yourself unconscious is not the same as producing natural sleep architecture.==

Some drugs bludgeon you into a sedated state that looks like sleep but has the wrong stage structure (suppressed deep sleep and/or REM), builds tolerance, and creates dependence — and the moment you stop, your insomnia comes back worse (rebound). These are the wrong tools for a reset, because a reset is supposed to rebuild architecture and end with you off the drug.

Other drugs remove an obstacle to sleep — they switch off the wakefulness signal, or quiet the over-active nervous system — and then let your own machinery run a relatively normal night. These preserve architecture, don’t build much tolerance, and can be stopped cleanly. These are the right tools.

So as we go through each compound, the questions that matter are:

  • Does it preserve natural architecture (deep sleep + REM), or flatten it?
  • Does it build tolerance / dependence / rebound — i.e., can you actually get off it?
  • Does it harm breathing (a real danger if you have any sleep apnoea — central nervous system depressants relax the airway)?
  • Does it cost you anything in the daytime — grogginess, or blunted motivation and drive?

Why the "motivation" question is on the list

A lot of effective sleep drugs are repurposed antidepressants, which raises the obvious fear: will this flatten my drive? The answer is dose-dependent and compound-specific, and it’s important enough that it gets its own section below. For a driven person, “I sleep great but I’m a zombie with no ambition” is a failed outcome, not a success.

The 30-day reset strategy

This is the how that the rest of the article serves. The reset is a structured, time-limited protocol, not “take a pill when you can’t sleep.”

Why 30 days? Three things all need roughly that long:

  • Circadian re-anchoring. Your clock (Part 1.0) shifts slowly. A month of falling asleep at the same time every night, reinforced by morning light, drags your natural sleep window to where you want it.
  • Behavioural conditioning. “Bed = sleep” (stimulus control, Part 2.0) and the wind-down ritual (Part 2.1) are associations that take weeks of repetition to set. The drug guarantees the repetitions happen.
  • Architecture normalisation. After chronic deprivation, a month of consistent, deep, well-structured nights lets the body clear some of its debt and re-establish a normal stage pattern.

How to run it (the rule that makes or breaks the reset):

Run the drug and the full foundation simultaneously

The reset only works if you take the compound while also running Parts 2.0 and 2.1 perfectly — cold dark room, fixed wake time, morning light, caffeine cutoff, wind-down. The drug isn’t the reset; ==the drug is what buys you a month of compliance with the habits that are the real reset.== When you taper off, the habits are what’s left holding the architecture up. Take the pill, skip the habits, and you’ve just rented 30 nights of sleep and built nothing.

The shape of it: pick the right compound (below) → run it nightly with the full protocol for 2–4 weeks → then taper (the architecture-friendly compounds let you simply stop or step down) → rely on sunlight, the room, and the routine. If the problem returns the instant you stop, that usually means the foundation wasn’t actually in place — go back to Parts 2.0–3.0.

The cornerstone: DORAs

If one class is purpose-built for this reset, it’s the DORAs — Dual Orexin Receptor Antagonists. This is the newest and arguably smartest class of sleep medication, and it’s the cornerstone of the strategy.

The mechanism is the reason. Orexin (a.k.a. hypocretin) is the neuropeptide that keeps you awake — it’s the brain’s “stay alert” signal. DORAs block the orexin receptors, switching the wakefulness signal off. Crucially, they do not force sedation by hammering a depressant system. They simply remove the brain’s foot from the wakefulness pedal and let natural sleep happen.1 The consequences of that mechanism are exactly the four things we said to look for:

  • They preserve natural sleep architecture — normal-ish deep sleep and REM, rather than the flattened structure of sedatives.
  • No meaningful physical dependence, tolerance, or rebound insomnia — which is the property you want in a drug you intend to stop after 30 days. You can come off cleanly.
  • They don’t depress breathing the way GABAergic sedatives do, making them comparatively safer for people with sleep apnoea (still: get apnoea evaluated and treated — see the disclaimer).
  • They don’t touch dopamine, serotonin, or histamine — so there’s no emotional blunting and no hit to motivation or drive. For a driven person, this is the cleanest profile available.

The compounds (three exist; all work the same way):

  • Lemborexant (Dayvigo) — approved 2019; good for both sleep onset and maintenance.
  • Daridorexant (Quviviq) — approved 2022; the newest, designed for a clean morning (shorter functional hangover at the right dose).
  • Suvorexant (Belsomra) — approved 2014; the first of the class.

Dosing & timing (always physician-directed): typically started at the lower dose (e.g., lemborexant 5 mg, titratable to 10 mg) immediately before getting into bed, with at least 7 hours available to sleep.

The food rule (and the 9 PM meal connection)

Do not take a DORA with or right after a large meal. Food substantially delays absorption — so a DORA taken on top of a big 9 PM post-workout meal won’t help you fall asleep at 11 PM and instead lingers, leaving you groggy at 9 AM. Take it on a relatively empty stomach, right before bed. This is one more reason to fix the late-meal timing from Part 2.1.

The catch: cost. DORAs are new, on-patent, and expensive — by far the priciest option here. That’s the main reason they aren’t everyone’s default, and why the cheaper workhorses below exist as legitimate alternatives.

Why DORAs are the ideal reset tool

Clean architecture + no dependence + no rebound + no motivation hit = a drug you can run hard for 30 nights to force a perfect, well-structured pattern, then stop without a fight. That is precisely the brief. If budget allows, this is the cornerstone of the bridge.

Trazodone — the cheap workhorse

If DORAs are too expensive (the common case), trazodone is the most popular alternative for good reason. It’s a sedating antidepressant used off-label at micro-doses for sleep — and at those doses it behaves nothing like an antidepressant.2

At 25–50 mg (versus the 150–300 mg+ used for depression), trazodone blocks histamine (H1) and serotonin (5-HT2A) receptors to produce heavy, natural-feeling drowsiness.

Pros:

  • Very cheap — an affordable generic everywhere, including Malaysia.
  • Improves sleep quality — clinical data show it can increase deep sleep without destroying natural architecture (a real point of difference from sedatives).
  • Non-addictive — no chemical dependency; you can stop without rebound insomnia.
  • Good for maintenance — a longer half-life means it helps keep you asleep through the night, not just falling asleep. Strong fit if your problem is waking at 3 AM.

Cons:

  • Next-day grogginess — the longer half-life can leave a morning “hangover,” though this usually fades after about a week of consistent use.
  • Mild blood-pressure drop / dizziness — it blocks alpha-1 receptors, which can cause lightheadedness on standing up quickly at night (orthostatic). Rise slowly.
  • Rare but serious: priapism (seek care). A doctor will screen for interactions (it shouldn’t be combined with certain antidepressants).

Why low-dose trazodone won’t kill your drive

This deserves its own section because it’s the fear that stops driven people from using an otherwise ideal cheap tool — and the fear is misplaced at sleep doses.

When psychiatrists treat depression, they use 150–300 mg+ of trazodone, where it changes how serotonin moves in the brain to alter mood. When doctors prescribe it for sleep, they use 25–50 mg — a fraction — and at that dose:

  • The histamine/serotonin “lock,” not a mood change. 25–50 mg isn’t strong enough to shift your baseline serotonin or daytime mood. It only binds H1 histamine (a heavy, natural drowsiness, like a strong antihistamine) and 5-HT2A (calming the fight-or-flight system). It’s a localised night-time off-switch, not a personality drug.
  • Clean burnout. Trazodone has a relatively short half-life for an antidepressant; the bulk of a 25 mg dose taken at 11 PM is cleared by morning.
  • No dopamine blunting. The drugs famous for crushing motivation and drive are the SSRIs (Lexapro, Zoloft), which can blunt dopamine pathways over time. Trazodone doesn’t touch the dopamine system — your baseline drive stays intact.

What it actually feels like

Not “drugged” or flattened the next day — just like you had a very heavy, deep night of sleep. The only common early issue is ~30 minutes of physical “inertia” on waking in the first 4–7 days, which clears once you’re up, hydrated, and into your morning light routine. If the idea of an antidepressant still sits wrong with you despite this, that’s exactly what the DORAs (zero psychiatric crossover) are for — you just pay more for the peace of mind.

Doxepin — the maintenance specialist

Doxepin is a tricyclic antidepressant that, at micro-doses of 3–6 mg (sold as Silenor, but cheap as a generic), becomes a highly selective histamine (H1) blocker — it switches off the receptors that keep you alert without knocking out the whole central nervous system.3

  • Pros: very cheap generic; considered one of the best low-cost drugs for sleep maintenance (staying asleep, not waking repeatedly); zero addiction potential; well-tolerated; it’s the only TCA with low-dose FDA approval specifically for insomnia.
  • Cons: mild dry mouth and slight grogginess in the first week. (Note: at low dose the anticholinergic burden is much smaller than the OTC antihistamines warned about in Part 3.0, but it’s still a consideration over the long term — which is another argument for the time-limited reset rather than indefinite use.)

Mirtazapine — effective, with a catch

Mirtazapine (Remeron) is another older antidepressant used off-label for sleep at low doses (3.75–7.5 mg), where it acts as a massive antihistamine, causing deep, heavy drowsiness.

  • Pros: cheap, non-habit-forming, no benzodiazepine/Z-drug addiction risk, and it preserves deep sleep well.
  • The catch (and it’s a big one for a lifter): it massively increases appetite. For anyone managing body fat or in a cutting phase, the intense next-day cravings can wreck diet adherence. It can also cause a heavy morning hangover.

Right drug, wrong user

Mirtazapine is genuinely effective and architecture-friendly, but the appetite effect makes it a poor fit for a physique-focused reader — the exact opposite of what you want mid-cut. Useful to know it exists (and that the appetite effect is occasionally exploited in underweight patients), but for most readers here, trazodone or doxepin does the same job without the hunger.

The circadian accelerators: agomelatine and ramelteon

A separate, elegant path for the reader who wants zero association with psychiatric sedation and wants to protect (or even boost) daytime drive. Instead of sedating you, these work the circadian angle from Part 1.0 — they help re-time the clock, which is exactly what a 30-day reset is trying to do.

  • Agomelatine (Valdoxan): a melatonergic (MT1/MT2) agonist plus 5-HT2C antagonist. The melatonergic action resynchronises the circadian rhythm (a far better-designed version of what people think melatonin does), pulling your body clock toward an earlier, consistent sleep time. The 5-HT2C antagonism causes a localised daytime release of dopamine and noradrenaline in the prefrontal cortex — so it can actually clear brain fog and support motivation during the day, which is uniquely appealing for a heavy trainer and driven professional. The catch: it can affect the liver — LFT (liver function) monitoring is required, especially early, and it’s avoided in those with liver issues. (Note it’s approved in Europe/Malaysia but not the US.)
  • Ramelteon (Rozerem): a pure, potent melatonin-receptor (MT1/MT2) agonist. A clean circadian shifter for sleep onset, with no abuse potential and no crossover with mood or motivation whatsoever.4 Genuinely safe profile; best for people whose problem is falling asleep / a delayed clock rather than staying asleep.

Two strategic paths (from the cost-vs-mechanism angle)

  • Path A — Circadian & drive-protecting (agomelatine or ramelteon): for zero psychiatric-sedation association and untouched (or enhanced) daytime focus. Pricier; agomelatine needs liver monitoring.
  • Path B — Micro-dose cost optimisers (trazodone 25 mg or doxepin 3 mg): for rock-bottom cost without sacrificing drive, since these doses don’t blunt dopamine or alter personality — just a localised night-time off-switch.
  • The cornerstone — DORAs: the cleanest architecture + no-dependence profile of all, if budget allows.

The anti-pattern: Z-drugs and benzodiazepines

These are the drugs to understand specifically so you avoid them for a reset. They are effective at causing unconsciousness and are exactly the wrong tool for the job here.

Z-drugs — zolpidem (Stilnox/Ambien), zopiclone, eszopiclone — are hypnotics that rapidly force the brain’s GABA receptors to shut down activity. Benzodiazepines (alprazolam/Xanax, diazepam, etc.) work on the same GABA system and are even worse for sleep architecture.

  • Pros (the seduction): zolpidem works fast (15–20 min) and, being short-acting, often leaves little morning hangover. If your mind is racing, it will force you under.
  • Why they fail the reset test:
    • High dependence and tolerance. Use nightly for more than ~2 weeks and your brain adapts; you’ll struggle to sleep without it, and stopping triggers rebound insomnia worse than baseline. This is the precise opposite of a drug you can walk off after 30 days — it builds the dependence the reset is meant to avoid.
    • Degraded architecture. GABAergic sedation doesn’t reproduce natural deep sleep and REM well — you’re sedated, not restored.
    • The apnoea / heart-rate danger. Because they heavily relax the central nervous system and throat muscles, they carry the highest risk of worsening sleep apnoea of anything here. If a drug stops you breathing properly at night, your overnight and daytime resting heart rate climb right back up — the exact recovery marker from Part 1.0 you were trying to fix. Especially relevant for anyone on TRT or enhanced (higher apnoea risk to begin with — see Performance Enhancement Part 4.0).
    • Complex sleep behaviours. Zolpidem in particular can cause sleepwalking, sleep-eating, sleep-driving, and amnesia — serious enough that regulators carry boxed warnings.5
    • Poor maintenance. Standard zolpidem wears off in 4–6 hours — it gets you down at 11 PM but may let you wake at 4 AM.

The honest place for Z-drugs

Very short-term, occasional rescue under medical supervision (a few nights through an acute crisis or time-zone emergency) — never the 30-day bridge, and never a nightly habit. If a doctor reaches for zolpidem for chronic insomnia, it’s worth asking about a DORA or low-dose trazodone instead, both of which are far better suited to rebuilding sleep rather than just sedating it. In Malaysia, zolpidem (Stilnox) is a controlled medicine for exactly these reasons.

The master comparison table

MedicationCostHeart-rate / apnoea riskAddiction / dependenceDaytime motivation & driveSleep quality (deep & REM)
DORAs (lemborexant, daridorexant, suvorexant)Very highVery low — doesn’t depress breathingNone to minimal — clean to stopNone — turns off wakefulness; no bluntingExcellent — preserves natural architecture
Agomelatine (Valdoxan)Moderate–highNone — no respiratory suppressionNoneCan improve drive — ↑ dopamine/noradrenaline in PFCExcellent — resynchronises circadian rhythm (needs LFT monitoring)
Ramelteon (Rozerem)Moderate–highNoneNone — 0% abuse/reboundNone — pure melatonin pathwayGood — mainly assists sleep onset
Trazodone (25–50 mg micro-dose)Very lowLowNone — non-habit-formingNone at low dose — localised off-switch, no dopamine hitExcellent — actively increases deep sleep
Doxepin (3–6 mg micro-dose)Very low (generic)Very lowNoneNone to low — H1-selective at this doseExcellent — superb for sleep maintenance
Mirtazapine (3.75–7.5 mg)LowLowNoneLow — but massively ↑ appetite (diet killer)Good — preserves deep sleep; morning hangover
Z-drugs / benzos (zolpidem etc.)Low–moderateHigh — relaxes airway, worsens apnoeaHigh — tolerance, dependence, reboundVariable; amnesia/complex behavioursPoor — sedation, not natural architecture

Choosing your compound

The decision comes down to a few honest questions:

  • Onset vs. maintenance? Trouble falling asleep → ramelteon, a DORA, or trazodone. Waking at 3–4 AM (maintenance) → doxepin or trazodone (longer-acting), or a DORA (both).
  • Budget? Tight → trazodone 25 mg or doxepin 3 mg (Path B). Comfortable, want the cleanest profile → DORA (cornerstone).
  • Worried about drive / hate the idea of a psych med? → DORA (zero crossover) or the circadian Path A (ramelteon; agomelatine, which may even help drive).
  • Circadian/shift problem (clock in the wrong place)? → the accelerators (agomelatine, ramelteon) or a DORA, all paired hard with morning light.
  • Sleep apnoea or on TRT/enhanced? → avoid Z-drugs/benzos; favour DORAs (and treat the apnoea).
  • Cutting / managing body fat? → avoid mirtazapine (appetite).

The defensible defaults

For most driven readers running a deliberate reset: a DORA if budget allows (cleanest, easiest to stop), or low-dose trazodone if it doesn’t (cheap, architecture-friendly, maintenance-strong, drive-safe). Both are excellent bridges. The accelerators are the specialist pick for a clock that’s in the wrong place.

Running the reset

Putting it together into the actual protocol:

  1. Earn it. Confirm Parts 2.0, 2.1, and 3.0 are genuinely in place. This article assumes that.
  2. See a doctor. Bring your sleep log and your reasoning; discuss the compound that fits (this article is your briefing for that conversation, not a substitute for it). For agomelatine, get baseline liver function tests and follow the monitoring schedule.
  3. Run the bridge for 2–4 weeks, nightly, at a fixed bedtime — simultaneously running the full environment and protocol. Same wake time every day; morning light every day. Observe the DORA food/empty-stomach rule if you’re on one.
  4. Track the scoreboard. Overnight resting heart rate and HRV (Part 1.0) and how you feel at 10 AM. You want RHR trending down and mornings clearer.
  5. Taper and hand off. With the architecture-friendly compounds (DORA, trazodone, doxepin, ramelteon) you can step down or stop relatively cleanly. The habits — clock now anchored, bed reconditioned for sleep, ritual automatic — carry it.
  6. If it relapses on stopping, the foundation wasn’t really there. Return to Parts 2.0–3.0; the drug was never going to be the permanent answer. Consider formal CBT-I with a professional — the most durable fix of all.

The whole point, one more time

The reset succeeds when you no longer need it. You used a month of pharmacologically-guaranteed good sleep to install the architecture and the habits — and then you live on the free, permanent foundation from Parts 1–2. A drug you can’t stop isn’t a reset; it’s a dependency, and the compounds chosen here were chosen precisely so that doesn’t happen.

Part 3.1 Takeaways

Key concepts to internalize

  • The drug is a 30-day bridge, not a crutch — used to force consistent, well-architected sleep long enough to re-anchor the clock and condition the habits, then tapered off. It only works run alongside the full 2.0/2.1 foundation.
  • Sedation ≠ sleep. Good drugs preserve architecture and can be stopped cleanly; bad ones sedate, flatten architecture, and build dependence.
  • DORAs are the cornerstone (lemborexant/Dayvigo, daridorexant/Quviviq, suvorexant/Belsomra): switch off the orexin wakefulness signal → natural architecture, no dependence/rebound, breathing-safe, no motivation hit. Downside: expensive, and don’t take on a full stomach.
  • Trazodone 25–50 mg = the cheap, architecture-friendly workhorse, great for maintenance; at sleep doses it doesn’t blunt drive (no dopamine hit — that’s the SSRIs). Doxepin 3–6 mg = cheap maintenance specialist. Mirtazapine works but wrecks your diet (appetite).
  • Agomelatine & ramelteon = the circadian accelerators — re-time the clock, protect (agomelatine may boost) daytime drive; agomelatine needs liver monitoring.
  • Avoid Z-drugs/benzos for a reset — dependence, rebound, degraded architecture, and the worst apnoea/breathing risk (which spikes your RHR — the opposite of recovery). Rescue use only.
  • Success = no longer needing it. Bridge, install habits, walk off. If it relapses on stopping, the foundation wasn’t there — and CBT-I is the most durable fix.

Your Reset Task List

  1. Verify the prerequisites. Have you truly run 2.0 + 2.1 + 3.0 for weeks? If not, this article isn’t for you yet.
  2. Bring a sleep log to a doctor and have the informed conversation — use this article to ask about DORAs / low-dose trazodone rather than defaulting to a Z-drug.
  3. Match compound to problem: onset vs. maintenance, budget, drive concern, apnoea/TRT, cutting. Note the defensible defaults (DORA, or trazodone if cost-bound).
  4. Plan the 30 days: fixed bedtime + wake time, full environment + protocol every night, DORA empty-stomach rule, baseline LFTs if agomelatine.
  5. Track RHR/HRV and mornings across the month.
  6. Plan the taper and the handoff to habits from day one — decide your off-ramp before you start, and consider professional CBT-I for a durable fix.

The series, complete

That’s the full ladder: understand the architecture → build the room → run the protocol → add natural support → and, only if truly needed, use a pharmacological reset as a bridge back to a foundation that holds on its own. Climb only as high as you need, and aim to come back down.

Disclaimer

Every drug discussed here is prescription-only (and several are controlled medicines in Malaysia, including zolpidem). Nothing in this article is medical advice, a prescription, or encouragement to obtain or self-medicate with any compound. Doses are illustrative of standard clinical/harm-reduction ranges, not a dosing instruction. These medications carry real risks and interactions — trazodone (orthostatic hypotension, priapism, serotonergic interactions), agomelatine (hepatotoxicity — requires liver monitoring), DORAs (next-day impairment, rare sleep paralysis), antidepressants (interactions, and never combine certain ones), and Z-drugs/benzodiazepines (dependence, complex sleep behaviours, respiratory risk).

Loud snoring, gasping, or pauses in breathing point to sleep apnoea, which several of these drugs can worsen and which sedating yourself will not fix — get it evaluated first. Insomnia tied to anxiety, depression, or another medical condition needs that condition treated. Work with a qualified doctor (and consider CBT-I, the evidence-based first-line treatment), pull any monitoring your compound requires, and understand what you’re taking before you take it.

Sources & references

Footnotes

  1. Dual orexin receptor antagonists (DORAs): orexin/hypocretin is the wakefulness-promoting neuropeptide, and DORAs promote sleep by blocking OX1/OX2 receptors while largely preserving sleep architecture, with low dependence/rebound liability. FDA approvals: suvorexant (Belsomra) 2014, lemborexant (Dayvigo) 2019, daridorexant (Quviviq) 2022. See Muehlan, C. et al. (2020) and the daridorexant first-approval review, Drugs (2022) — PMC9042981. ↩

  2. Trazodone for insomnia (low-dose, off-label): Jaffer, K.Y. et al. (2017), “Trazodone for Insomnia: A Systematic Review,” Innovations in Clinical Neuroscience 14(7–8):24–34 — reviews the 25–100 mg sleep dose, the H1/5-HT2A mechanism, preserved/increased slow-wave sleep, and the non-dependence profile. The dose-dependent separation from antidepressant effects is discussed in Mendelson, W.B. (2005), Journal of Clinical Psychiatry 66(4):469–476. ↩

  3. Low-dose doxepin: Krystal, A.D. et al.; doxepin 3 mg and 6 mg (Silenor) is FDA-approved for sleep-maintenance insomnia, acting as a selective H1 antagonist at these doses with minimal anticholinergic effect relative to higher TCA doses. ↩

  4. Ramelteon: a selective MT1/MT2 melatonin-receptor agonist for sleep-onset insomnia, with no appreciable abuse potential and no effect on mood/cognition pathways. Agomelatine combines MT1/MT2 agonism with 5-HT2C antagonism (the latter increasing prefrontal dopamine/noradrenaline) and requires periodic liver-function monitoring due to hepatotoxicity risk (EMA prescribing information for Valdoxan). ↩

  5. Z-drugs and complex sleep behaviours: the US FDA added a boxed warning in 2019 for zolpidem, eszopiclone, and zaleplon following reports of complex sleep behaviours (sleepwalking, sleep-driving, sleep-eating) resulting in serious injury. GABAergic hypnotics and benzodiazepines also carry dependence/tolerance/rebound liability and can worsen obstructive sleep apnoea via airway-muscle relaxation and respiratory depression. ↩

Graph View

Backlinks